alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › comparison

comparison

10 studies tagged comparison, dated 2014-05-29 to 2025-04-01. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. A comparison of p-tau assays for the specificity to detect tau changes in Alzheimer's disease 2025-04-01
  2. Plasma p-tau181 and amyloid markers in Alzheimer's disease: A comparison between Lumipulse and SIMOA 2024-08-22
  3. Comparison of plasma soluble and extracellular vesicles-associated biomarkers in Alzheimer's disease patients and cognitively normal individuals 2024-06-28

Studies

10 studies carry this tag.

Date range

2014 to 2025

Top journals

  • Alzheimer's research & therapy 2
  • Alzheimer's & dementia (Amsterdam, Netherlands) 1
  • Alzheimer's & dementia : the journal of the Alzheimer's Association 1
  • Clinical chemistry and laboratory medicine 1
  • Frontiers in aging neuroscience 1

9 journals in all.

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. A comparison of p-tau assays for the specificity to detect tau changes in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 60 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2025-04-01 Biomarkers

    LMW-specific p-tau assays could be more useful in the diagnostic workup of AD, especially in population-based communities where conditions causing peripheral neuropathy are frequent.

  2. Plasma p-tau181 and amyloid markers in Alzheimer's disease: A comparison between Lumipulse and SIMOA

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. Neurobiology of aging 2024-08-22 Biomarkers

    One-hundred-thirthy-three participants, namely 55 A+T+N+ AD, 28 Neurodegenerative disorders (NDD) and 50 controls were enrolled for the study.

  3. Comparison of plasma soluble and extracellular vesicles-associated biomarkers in Alzheimer's disease patients and cognitively normal individuals

    ✓ Peer-reviewed alzhub usefulness score 57 out of 100. Alzheimer's research & therapy 2024-06-28 Biomarkers

    Soluble plasma Aβ42/40 ratio is the most robust biomarker to discriminate between AD patients and CN individuals, as it normalizes for the number of NDEVs.

  4. Comparison of plasma and neuroimaging biomarkers to predict cognitive decline in non-demented memory clinic patients

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Alzheimer's research & therapy 2024-05-16 Biomarkers

    Plasma NfL and GFAP predict cognitive decline in a similar manner to traditional imaging techniques in amyloid-positive MCI patients.

  5. Assessment of the Correlation and Diagnostic Accuracy between Cerebrospinal Fluid and Plasma Alzheimer's Disease Biomarkers: A Comparison of the Lumipulse and Simoa Platforms

    ✓ Peer-reviewed alzhub usefulness score 57 out of 100. International journal of molecular sciences 2024-04-23 Biomarkers

    We compared the clinical and analytical performance of Alzheimer's disease (AD) plasma biomarkers measured using the single-molecule array (Simoa) and Lumipulse platforms.

  6. Comparison of plasma and CSF biomarkers across ethnoracial groups in the ADNI

    ✓ Peer-reviewed alzhub usefulness score 53 out of 100. Alzheimer's & dementia (Amsterdam, Netherlands) 2022-05-01 Biomarkers

    Plasma and CSF AD biomarkers may perform similarly across diverse populations but future studies in large, diverse cohorts are needed.

  7. Correlations between serum and CSF pNfH levels in ALS, FTD and controls: a comparison of three analytical approaches

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Clinical chemistry and laboratory medicine 2019-09-01 Biomarkers

    Serum levels also correlated strongly with CSF levels for Simoa-based measurements (both ϱ = 0.62).

  8. Comparison of neurotoxicity of different aggregated forms of Aβ40, Aβ42 and Aβ43 in cell cultures

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Journal of peptide science : an official publication of the European Peptide Society 2017-02-16 Biomarkers

    The abnormal deposition of amyloid-β (Aβ) peptides in the brain is the main neuropathological hallmark of Alzheimer's disease (AD).

  9. Blood Beta-Amyloid and Tau in Down Syndrome: A Comparison with Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. Frontiers in aging neuroscience 2017-01-17 Biomarkers

    The Aβ-40 and tau levels were higher and the Aβ-42 level and Aβ-42/Aβ-40 ratio were lower in DS than in the controls (all p < 0.001).

  10. Practical detection of a definitive biomarker panel for Alzheimer's disease; comparisons between matched plasma and cerebrospinal fluid

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. International journal of molecular epidemiology and genetics 2014-05-29 Biomarkers

    Previous mass spectrometry analysis of cerebrospinal fluid (CSF) has allowed the identification of a panel of molecular markers that are associated with Alzheimer's disease (AD).

All topic tags with their study counts